search icon
mnpr-img

Monopar Therapeutics Inc, Common Stock

MNPR

NAQ

$32.39

-$0.07

(-0.22%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$216.72M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
19.37K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.13
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.72 L
$54.3 H
$32.39

About Monopar Therapeutics Inc, Common Stock

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMNPRSectorS&P500
1-Week Return-8.61%0.71%0.79%
1-Month Return-22.81%-5.6%6.04%
3-Month Return-7.75%-11.72%-1.11%
6-Month Return43.76%-10.81%-2.39%
1-Year Return944.84%-7.12%11.69%
3-Year Return202.71%-0.57%42.29%
5-Year Return-15.87%27.64%93.12%
10-Year Return-75.55%75.45%179.21%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue122.40K----[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit122.40K----[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin100.00%----[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses6.51M9.13M10.54M8.83M16.16M[{"date":"2020-12-31","value":40.27,"profit":true},{"date":"2021-12-31","value":56.47,"profit":true},{"date":"2022-12-31","value":65.2,"profit":true},{"date":"2023-12-31","value":54.64,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(6.51M)(9.13M)(10.54M)(8.83M)(16.16B)[{"date":"2020-12-31","value":-650887500,"profit":false},{"date":"2021-12-31","value":-912724800,"profit":false},{"date":"2022-12-31","value":-1053687700,"profit":false},{"date":"2023-12-31","value":-883123500,"profit":false},{"date":"2024-12-31","value":-1616172100000,"profit":false}]
Total Non-Operating Income/Expense286.20K48.05K42.48K772.66K575.71M[{"date":"2020-12-31","value":0.05,"profit":true},{"date":"2021-12-31","value":0.01,"profit":true},{"date":"2022-12-31","value":0.01,"profit":true},{"date":"2023-12-31","value":0.13,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(6.30M)(9.10M)(10.52M)(8.40M)(15.59B)[{"date":"2020-12-31","value":-630457300,"profit":false},{"date":"2021-12-31","value":-910322400,"profit":false},{"date":"2022-12-31","value":-1051563800,"profit":false},{"date":"2023-12-31","value":-840219600,"profit":false},{"date":"2024-12-31","value":-1558641900000,"profit":false}]
Income Taxes(81.90K)(24.02K)(21.24K)(8.83K)-[{"date":"2020-12-31","value":-8190200,"profit":false},{"date":"2021-12-31","value":-2402400,"profit":false},{"date":"2022-12-31","value":-2123900,"profit":false},{"date":"2023-12-31","value":-883123,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(6.22M)(9.08M)(10.49M)(8.39M)-[{"date":"2020-12-31","value":-622267100,"profit":false},{"date":"2021-12-31","value":-907920000,"profit":false},{"date":"2022-12-31","value":-1049439900,"profit":false},{"date":"2023-12-31","value":-839336477,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(6.30M)(9.10M)(10.52M)(9.48M)(15.59M)[{"date":"2020-12-31","value":-630457300,"profit":false},{"date":"2021-12-31","value":-910322400,"profit":false},{"date":"2022-12-31","value":-1051563800,"profit":false},{"date":"2023-12-31","value":-948461900,"profit":false},{"date":"2024-12-31","value":-1558641900,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(6.22M)(9.08M)(10.49M)(8.40M)(15.59B)[{"date":"2020-12-31","value":-622267100,"profit":false},{"date":"2021-12-31","value":-907920000,"profit":false},{"date":"2022-12-31","value":-1049439900,"profit":false},{"date":"2023-12-31","value":-840219600,"profit":false},{"date":"2024-12-31","value":-1558641900000,"profit":false}]
EPS (Diluted)(0.59)(0.74)(0.83)(0.61)(3.72)[{"date":"2020-12-31","value":-59,"profit":false},{"date":"2021-12-31","value":-74,"profit":false},{"date":"2022-12-31","value":-83,"profit":false},{"date":"2023-12-31","value":-61,"profit":false},{"date":"2024-12-31","value":-372,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MNPR
Cash Ratio 26.62
Current Ratio 36.92

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MNPR
ROA (LTM) -34.49%
ROE (LTM) -54.27%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MNPR
Debt Ratio Lower is generally better. Negative is bad. 0.03
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.97

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MNPR
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 3.70
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Monopar Therapeutics Inc share price today?

Monopar Therapeutics Inc (MNPR) share price today is $32.39

Can Indians buy Monopar Therapeutics Inc shares?

Yes, Indians can buy shares of Monopar Therapeutics Inc (MNPR) on Vested. To buy Monopar Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MNPR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Monopar Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Monopar Therapeutics Inc (MNPR) via the Vested app. You can start investing in Monopar Therapeutics Inc (MNPR) with a minimum investment of $1.

How to invest in Monopar Therapeutics Inc shares from India?

You can invest in shares of Monopar Therapeutics Inc (MNPR) via Vested in three simple steps:

  • Click on Sign Up or Invest in MNPR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Monopar Therapeutics Inc shares
What is Monopar Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Monopar Therapeutics Inc (MNPR) is $54.3. The 52-week low price of Monopar Therapeutics Inc (MNPR) is $1.72.

What is Monopar Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Monopar Therapeutics Inc (MNPR) is 3.70

What is the Market Cap of Monopar Therapeutics Inc?

The market capitalization of Monopar Therapeutics Inc (MNPR) is $216.72M

What is Monopar Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Monopar Therapeutics Inc is MNPR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top